Nicorandil ameliorated hypertensive renal injury without lowering blood pressure in spontaneously hypertensive rats

Pharmacology

Volumn 91, Issue 1-2, 2013, Pages 92-103

  Serizawa, Kenichi ^a   Yogo, Kenji ^a   Tashiro, Yoshihito ^a   Koike, Nobuo ^a   Aizawa, Ken ^a   Hirata, Michinori ^a   Ishizuka, Nobuhiko ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Endothelial nitric oxide synthase; Kidney; Nicorandil; Proteinuria; Spontaneously hypertensive rat

Indexed keywords

ACETYLGLUCOSAMINIDASE; BETA 2 MICROGLOBULIN; CREATININE; DRINKING WATER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; HEPARAN SULFATE; MESSENGER RNA; NICORANDIL; NITRIC OXIDE; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CELL DENSITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GENE EXPRESSION REGULATION; GLYCOCALYX; HEART SIZE; HISTOPATHOLOGY; HYPERTENSION; HYPERTENSIVE NEPHROPATHY; JUXTAGLOMERULAR CELL; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY SIZE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; WISTAR KYOTO RAT; BLOOD PRESSURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; TISSUE INJURY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HYPERTENSION; KIDNEY DISEASES; MALE; NICORANDIL; NITRIC OXIDE SYNTHASE TYPE III; PROTEINURIA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RNA, MESSENGER;

EID: 84872088338     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000345811     Document Type: Article

References (57)

1. Ruilope LM, Bakris GL: Renal function and target organ damage in hypertension. Eur Heart J 2011; 32: 1599-1604.
2. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropa-thies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364.
3. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
4. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87.
5. Weir MR, Hollenberg NK, Zappe DH, Meng X, Parving HH, Viberti G, Remuzzi G: Anti-hypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. J Hypertens 2010; 28: 186-193.
6. Ruggenenti P, Remuzzi G: Proteinuria: is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 2009; 5: 436-437.
7. Cravedi P, Ruggenenti P, Remuzzi G: Which antihypertensive drugs are the most nephro-protective and why? Expert Opin Pharmaco-ther 2010; 11: 2651-2663.
8. IONA Study Group: Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-1275.
9. Horinaka S, Yabe A, Yagi H, Ishimitsu T, Yamazaki T, Suzuki S, Kohro T, Nagai R: Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2010; 74: 503-509.
10. Ishii H, Toriyama T, Aoyama T, Takahashi H, Yamada S, Kasuga H, Ichimiya S, Kanashiro M, Mitsuhashi H, Maruyama S, Matsuo S, Naruse K, Matsubara T, Murohara T: Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther 2007; 29: 110-122.
11. Imagawa J, Baxter GF, Yellon DM: Myocar-dial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. J Cardiovasc Pharmacol 1998; 31: 74-79.
12. Tang XL, Xuan YT, Zhu Y, Shirk G, Bolli R: Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol 2004; 286:H1273-H1280.
13. Sekiya M, Sato M, Funada J, Ohtani T, Akut-su H, Watanabe K: Effects of the long-term administration of nicorandil on vascular en-dothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005; 46: 63-67.
14. Serizawa K, Yogo K, Aizawa K, Tashiro Y, Ishizuka N: Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats. Cardiovasc Diabetol 2011; 10: 105.
15. Sudo H, Hirata M, Kanada H, Yorozu K, Tashiro Y, Serizawa K, Yogo K, Kataoka M, Moriguchi Y, Ishizuka N: Nicorandil improves glomeru lar injury in rats with mesan-gioproliferative glomerulonephritis via inhibition of proproliferative and profibrotic growth factors. J Pharmacol Sci 2009; 111: 53-59.
16. Shimizu S, Saito M, Kinoshita Y, Ohmasa F, Dimitriadis F, Shomori K, Hayashi A, Satoh K: Nicorandil ameliorates ischaemia-reper-fusion injury in the rat kidney. Br J Pharmacol 2011; 163: 272-282.
17. Racasan S, Braam B, Koomans HA, Joles JA: Programming blood pressure in adult SHR by shifting perinatal balance of NO and reactive oxygen species toward NO: the inverted Barker phenomenon. Am J Physiol 2005; 288:F626-F636.
18. Megens RT, Reitsma S, Schiffers PH, Hilgers RH, De Mey JG, Slaaf DW, Oude Egbrink MG, van Zandvoort MA: Two-photon microscopy of vital murine elastic and muscular arteries. Combined structural and functional imaging with subcellular resolution. J Vasc Res 2007; 44: 87-98.
19. Martens-Lobenhoffer J, Bode-Boger SM: Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethyl-arginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 798: 231-239.
20. Nicholls SJ, Wang Z, Koeth R, Levison B, DelFraino B, Dzavik V, Griffith OW, Hathaway D, Panza JA, Nissen SE, Hochman JS, Hazen SL: Metabolic profiling of arginine and nitric oxide pathways predicts hemody-namic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction. Circulation 2007; 116: 2315-2324.
21. Bachmann S, Bosse HM, Mundel P: Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am J Physiol 1995; 268:F885-F898.
22. Wu F, Park F, Cowley AW Jr, Mattson DL: Quantification of nitric oxide synthase activity in microdissected segments of the rat kidney. Am J Physiol 1999; 276:F874-F881.
23. Plato CF, Shesely EG, Garvin JL: eNOS mediates L-arginine-induced inhibition of thick ascending limb chloride flux. Hypertension 2000; 35: 319-323.
24. Herrera M, Garvin JL: Recent advances in the regulation of nitric oxide in the kidney. Hypertension 2005; 45: 1062-1067.
25. Tomita N, Yamasaki K, Izawa K, Kunugiza Y, Osako MK, Ogihara T, Morishita R: Improvement of organ damage by a non-depressor dose of imidapril in diabetic spontaneously hypertensive rats. Int J Mol Med 2007; 19: 571-579.
26. Forbes MS, Thornhill BA, Park MH, Chevalier RL: Lack of endothelial nitric-oxide syn-thase leads to progressive focal renal injury. Am J Pathol 2007; 170: 87-99.
27. Kang DH, Nakagawa T, Feng L, Johnson RJ: Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 2002; 161: 239-248.
28. Horinaka S, Kobayashi N, Yabe A, Asakawa H, Yagi H, Mori Y, Tsubokou Y, Yoshida K, Nakano S, Matsuoka H: Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction. Cardiovasc Drugs Ther 2004; 18: 13-22.
29. Xu J, Nagata K, Obata K, Ichihara S, Izawa H, Noda A, Nagasaka T, Iwase M, Naoe T, Murohara T, Yokota M: Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension 2005; 46: 719-724.
30. Gilchrist M, Shore AC, Benjamin N: Inorganic nitrate and nitrite and control of blood pressure. Cardiovasc Res 2011; 89: 492-498.
31. Lundberg JO, Carlström M, Larsen FJ, Weitzberg E: Roles of dietary inorganic nitrate in cardiovascular health and disease. Cardiovasc Res 2011; 89: 525-532.
32. Carlström M, Persson AE, Larsson E, Hezel M, Scheffer PG, Teerlink T, Weitzberg E, Lundberg JO: Dietary nitrate attenuates oxi-dative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension. Cardiovasc Res 2011; 89: 574-585.
33. Bhatt SR, Lokhandwala MF, Banday AA: Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur J Pharmacol 2011; 667: 258-264.
34. Knight SF, Yuan J, Roy S, Imig JD: Simvas-tatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. Am J Physiol Renal Physiol 2010; 298:F86-F94.
35. Ono H, Ono Y, Takanohashi A, Matsuoka H, Frohlich ED: Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension 2001; 38: 1300-1306.
36. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG: Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-1209.
37. Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM: Disease-dependent mechanisms of albuminuria. Am J Physiol 2008; 295:F1589-F1600.
38. Floege J, Johnson RJ, Gordon K, Iida H, Pritzl P, Yoshimura A, Campbell C, Alpers CE, Couser WG: Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 1991; 40: 477-488.
39. Segawa K, Minami K, Shiga Y, Shiraishi M, Sata T, Nakashima Y, Shigematsu A: Inhibitory effects of nicorandil on rat mesangial cell proliferation via the protein kinase G pathway. Nephron 2001; 87: 263-268.
40. Hilliard LM, Russo LM, Comper WD: Hypertension-mediated albuminuria is associated with reduced lysosomal activity in the kidney and the heart. Am J Nephrol 2009; 29: 454-464.
41. Florian JA, Kosky JR, Ainslie K, Pang Z, Dull RO, Tarbell JM: Heparan sulfate proteogly-can is a mechanosensor on endothelial cells. Circ Res 2003; 93:e136-e142.
42. Ihrcke NS, Wrenshall LE, Lindman BJ, Platt JL: Role of heparan sulfate in immune system-blood vessel interactions. Immunol Today 1993; 14: 500-505.
43. Satoh M, Kobayashi S, Kuwabara A, Tomita N, Sasaki T, Kashihara N: In vivo visualization of glomerular microcirculation and hy-perfiltration in streptozotocin-induced diabetic rats. Microcirculation 2010; 17: 103-112.
44. Jeansson M, Björck K, Tenstad O, Haralds-son B: Adriamycin alters glomerular endo-thelium to induce proteinuria. J Am Soc Nephrol 2009; 20: 114-122.
45. Kumase F, Morizane Y, Mohri S, Takasu I, Ohtsuka A, Ohtsuki H: Glycocalyx degradation in retinal and choroidal capillary endo-thelium in rats with diabetes and hypertension. Acta Med Okayama 2010; 64: 277-283.
46. Marsen TA, Schramek H, Dunn MJ: Renal actions of endothelin: linking cellular signaling pathways to kidney disease. Kidney Int 1994; 45: 336-344.
47. Hargrove GM, Dufresne J, Whiteside C, Muruve DA, Wong NC: Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 2000; 58: 1534-1545.
48. Kelly DJ, Skinner SL, Gilbert RE, Cox AJ, Cooper ME, Wilkinson-Berka JL: Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int 2000; 57: 1882-1894.
49. Gross ML, Ritz E, Schoof A, Helmke B, Parkman A, Tulp O, Munter K, Amann K: Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-con-verting enzyme inhibitor and endothelin receptor blocker. Lab Invest 2003; 83: 1267-1277.
50. Lee TM, Chang NC: Effect of nicorandil on proteinuria in well controlled hypertensive patients. J Hypertens 2009; 27: 618-625.
51. Sharma M, Zhou Z, Miura H, Papapetropoulos A, McCarthy ET, Sharma R, Savin VJ, Lianos EA: ADMA injures the glomerular filtration barrier: role of nitric oxide and super-oxide. Am J Physiol 2009; 296:F1386-F1395.
52. Hsu CN, Huang LT, Lau YT, Lin CY, Tain YL: The combined ratios of L-arginine and asymmetric and symmetric dimethylargi-nine as biomarkers in spontaneously hypertensive rats. Transl Res 2012; 159: 90-98.
53. Tanabe K, Lanaspa MA, Kitagawa W, Rivard CJ, Miyazaki M, Klawitter J, Schreiner GF, Saleem MA, Mathieson PW, Makino H, Johnson RJ, Nakagawa T: Nicorandil as a novel therapy for advanced diabetic ne-phropathy in the eNOS deficient mouse. Am J Physiol 2012; 302:F1151-F1160.
54. Horinaka S, Kobayashi N, Higashi T, Hara K, Hara S, Matsuoka H: Nicorandil enhances cardiac endothelial nitric oxide synthase expression via activation of adenosine triphos-phate-sensitive K channel in rat. J Cardio-vasc Pharmacol 2001; 38: 200-210.
55. + channels in the kidney. Naunyn Schmiedebergs Arch Pharmacol 1996; 354: 213-225.
56. Nakamura Y, Ono H, Zhou X, Frohlich ED: Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotec-tion in N(omega)-nitro-L-arginine methyl ester/spontaneously hypertensive rats. Hypertension 2001; 37: 1262-1267.
57. ATP channel conductance of descending vasa recta pericytes. Am J Physiol 2005; 289:F1235-F1245.